阿斯利康关于银翘病的床报告.docVIP

May. 9, 2014 Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif.?and?LONDON,?May 9, 2014?/PRNewswire/ --?Amgen?(NASDAQ: AMGN) andAstraZeneca?today announced that the Phase 3 AMAGINE-1TM?study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment